Update on the management of Lennox-Gastaut syndrome with a focus on rufinamide

Related Experiment Videos

Carl E Stafstrom1

  • 1Section of Pediatric Neurology, Departments of Neurology and Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. stafstrom@neurology.wisc.edu

Neuropsychiatric Disease and Treatment
|November 10, 2009
PubMed

Insights

Rufinamide effectively reduces seizure frequency in children over 4 with Lennox-Gastaut syndrome, an intractable childhood epilepsy. This anticonvulsant is generally well-tolerated, offering a promising adjunctive treatment option.

Area of Science:

  • Neurology
  • Pediatric Epilepsy
  • Pharmacology

Background:

  • Lennox-Gastaut syndrome is a severe, intractable epileptic encephalopathy in early childhood.
  • Current treatment options for Lennox-Gastaut syndrome are limited, necessitating novel therapeutic approaches.

Purpose of the Study:

  • To review the treatment of Lennox-Gastaut syndrome.
  • To focus on the efficacy and safety of rufinamide, a recently approved anticonvulsant, for this condition.

Main Methods:

  • Systematic literature search of PubMed.
  • Review of existing studies on Lennox-Gastaut syndrome treatment.
  • Analysis of studies involving rufinamide as an anticonvulsant.

Main Results:

  • Rufinamide demonstrated a beneficial effect in children over 4 years old with Lennox-Gastaut syndrome.
  • Significant reductions in tonic, atonic, and total seizure frequency were observed compared to placebo.
  • Rufinamide was generally well-tolerated, with somnolence and vomiting as the most common side effects.

Conclusions:

  • Rufinamide presents as a promising adjunctive therapy for Lennox-Gastaut syndrome.
  • Clinicians should be aware of rufinamide's clinical response profile and potential adverse effects for optimal use.
  • Further understanding of rufinamide's role in managing intractable childhood epilepsy is warranted.
Abstract

Keywords:
Lennox-Gastaut syndromeepilepsyepileptic encephalopathypediatricrufinamide

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Dysrhythmias VII: Nursing Management of Dysrhythmias01:25

Dysrhythmias VII: Nursing Management of Dysrhythmias

Nursing management of dysrhythmias involves the following:AssessmentSubjective Assessment:The initial step involves gathering patient-reported symptoms such as dizziness, palpitations, and chest discomfort. It is crucial to collect a detailed history, including previous heart conditions, current medication use, and lifestyle factors like caffeine and alcohol consumption.Objective Assessment:This involves observing clinical signs such as jugular venous distention, cool and pale skin, and...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...